Boston University School of Medicine

Core curriculum

Archived webinar


CME information


  Create an account or log in to participate in this activity

What is SCOPE of Pain?

Chronic pain affects approximately 100 million in the US, making it one of the most common reasons for patients to seek medical care. Unfortunately, pain management, including the appropriate use of opioids, is not well covered in medical training. Moreover, there are inadequate numbers of pain management specialists to help generalist providers manage these patients.

Partly in response to the problem of under-treatment of pain, over the past decade there has been a four-fold increase in opioid prescribing. During the same time period there was a four-fold increase in unintentional opioid overdose deaths and a five-fold increase in substance abuse treatment admissions for prescription opioid addiction.

Providers who prescribe ER/LA opioid analgesics to treat chronic pain are in a key position to balance the benefits and risks of chronic opioid therapy (COT). However, providers struggle with the need to assist their patients with adequate management of chronic pain while confronting the risks associated with opioid prescribing. Our educational program looks to address that need.

The SCOPE of Pain archived webinar is designed to help you safely and effectively manage patients with chronic pain, when appropriate, with opioid analgesics.

The FDA has mandated manufacturers of extended release/long-acting (ER/LA) opioid analgesics, as part of a comprehensive Risk Evaluation and Mitigation Strategy (REMS), to make available comprehensive prescriber education in the safe use of these medications based on the FDA curriculum known as the Blueprint for Prescriber Education for Extended Release and Long-Acting Opioid(ER/LA) Analgesics. Our curriculum covers all aspects of this blueprint and more to provide a comprehensive educational program.

Faculty

Daniel P. Alford, MD, MPH, is Professor of Medicine, Associate Dean of Continuing Medical Education and Director of the Safe and Competent Opioid Prescribing Education (SCOPE of Pain) program at Boston University School of Medicine. He is on staff in the Section of General Internal Medicine and Director of the Clinical Addiction Research and Education (CARE) Unit at Boston Medical Center. He is Director of the Boston University Evidence-based SBIRT Training (BESST) Project, the Massachusetts SBIRT Training and Technical Assistance (MASBIRT TTA) program and the Boston Sustainable Models for unhealthy Alcohol use ReducTion (B SMART) program. He is past-president of the Association for Medical Education and Research in Substance Abuse. In 2011 he was recognized as a "Champion of Change" by the White House. He has received the American Medical Association's "Award for Health Education", the American Society of Addiction Medicine first "Educator of the Year Award" and the American College of Physicians "Award for Distinguished Contributions to Behavioral Medicine". His clinical, educational and research interests focus on managing opioid use disorders and safer and more competent opioid prescribing for treating pain.

Jessica Taylor, MD, is an Assistant Professor of Medicine at Boston University School of Medicine (BUSM) and a primary care physician at Boston Medical Center, where her clinical work focuses on substance use disorders, HIV, and HIV prevention. She completed her medical education at the Mount Sinai School of Medicine in New York, NY and trained in internal medicine at Beth Israel Deaconess Medical Center in Boston, MA, where she was a member of the HIV Primary Care track. She served as the ambulatory chief resident at Beth Israel Deaconess Medical Center before joining faculty at BUSM. She provides clinical care to patients with substance use disorders in the General Internal Medicine Office Based Addiction Treatment (OBAT) program, in the Center for Infectious Diseases, and in Faster Paths, a new opioid urgent care clinic. Dr. Taylor also serves as the medical director of the Massachusetts Office Based Addiction Treatment (OBAT) ECHO, a tele-education series for Massachusetts providers interested in learning more about the management of substance use disorders.

Accreditation

Physicians

Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Boston University School of Medicine designates this live internet activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Contact Hours: 2.5, all of which is pharmacology credit-worthy
Nurses will receive contact hours after completion of a post-test and evaluation.

AAFP

This Live activity, SCOPE of Pain: Safer/Competent Opioid Prescribing Education, from 02/28/2019 - 02/28/2020, has been reviewed and is acceptable for up to 2.00 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Part 2

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Grant support

This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see ce.opioidanalgesicrems.com/RpcCEUI/rems/pdf/resources/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the US Food and Drug Administration.

Target audience

Physicians, nurse practitioners, registered nurses, physician assistants, nurses, dentists, pharmacists, and allied health professionals whose practices manage acute and chronic pain.

Educational objectives

Disclosure policy

Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve any apparent conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

Faculty

Daniel P. Alford, MD, MPH, FACP, FASAM (Course Director/Content Development)
Associate Dean of Medicine
Boston University School of Medicine
Boston Medical Center
Faculty member has no relevant financial relationships to disclose.
dan.alford@bmc.org

Jessica Taylor, MD (Content Development)
Assistant Professor of Medicine
Boston University School of Medicine
Boston Medical Center
Faculty member has nothing to disclose with regards to commercial support.
jessica.taylor@bmc.org

Ilana Hardesty, BA (Moderator)
Senior Operations Manager, SCOPE of Pain
Boston University School of Medicine
Faculty member has nothing to disclose with regards to commercial support.

Kristin Wason, NP (CNE Course Advisor)
Department of Internal Medicine
Boston University School of Medicine
Boston Medical Center
Faculty member has no relevant financial relationships to disclose.
kristin.wason@bmc.org

Planning Committee
Brian Jack, MD, independent AAFP reviewer
Ilana Hardesty, Senior Operations Manager, Boston University School of Medicine CME Office
Carmela Townsend, DNP, MS/MBA, RN, Lead Nurse Planner, Boston University School of Medicine CME Office
Jason Worcester, MD, independent CME reviewer
Stephen A. Wyatt, DO, independent CME reviewer
Planning committee members have no relevant financial relationships to disclose.

Off-label/investigational uses

This presentation does include discussion of the off-label use of sublingual buprenorphine to treat pain. Sublingual buprenorphine has been FDA approved for addiction treatment but not pain treatment. This presentation does include discussion of the off-label use of clonidine and tizanidine to treat opioid withdrawal symptoms. Clonidine and tizanidine are not FDA approved for this use.

Disclaimer

THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING MEDICAL EDUCATION ACTIVITIES ARE INTENDED SOLELY FOR PURPOSES OF SUPPLEMENTING CONTINUING MEDICAL EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS. ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND ALL RISK FOR THEIR APPROPRIATE USE. TRUSTEES OF BOSTON UNIVERSITY MAKES NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS. IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS. IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.

Boston University Council of Medical Specialty Societies Federation of State Medican Boards